HepVu and NASTAD are joining forces to develop an inaugural viral hepatitis surveillance status report to assess how jurisdictions across the U.S. are measuring the impact of viral hepatitis on their communities, identify best practices, and highlight areas in need of additional resources.
HepVu, an interactive online mapping tool that visualizes the impact of the viral hepatitis epidemics on communities across the United States to increase disease awareness and promote data-driven public health decision-making, and NASTAD, a leading non-partisan non-profit association that represents public health officials who administer HIV and viral hepatitis programs in the U.S. to end HIV/AIDS, viral hepatitis, and intersecting epidemic, will release the first report in 2022. Annual updates will be made, facilitating monitoring of changes and improvements in surveillance practices by jurisdiction.
To assess surveillance practices in jurisdictions, HepVu and NASTAD worked with a steering committee comprised of state and local health department representatives, national policy/advocacy organizations, and researchers (see full list below) to develop a set of indicators, determine process, and establish outputs for the results. Each year, HepVu and NASTAD will collect data from jurisdictions on these indicators, analyze the results, and prepare a status report describing findings nationally and by jurisdiction.
The initial survey was sent to jurisdictions in mid-March for response. If your jurisdiction has any questions about your response or the report, please contact firstname.lastname@example.org.
Viral Hepatitis Surveillance Status Report Steering Committee:
- Tyler Bartholomew, PhD, Director of Research and Evaluation; Assistant Professor, IDEA Exchange; University of Miami
- Sonia Canzater, MPH, JD, Associate Director, Hepatitis Policy Project, O’Neill Institute, Georgetown University Law Center
- Colleen Flanigan, Director, Bureau of Hepatitis Health Care, New York State Department of Health
- Jessica Fridge, MSPH, Surveillance Program Manager, STD/HIV Program, Louisiana Department of Health
- Ami Gandhi, MPH, Viral Hepatitis Epidemiology Lead, Georgia Department of Public Health
- Anne Gaynor, PhD, Manager of HIV, Hepatitis, STD and TB Programs, Association of Public Health Laboratories (APHL)
- Sara Glick, PhD, MPH, Associate Professor Department of Medicine, Division of Allergy & Infectious Diseases; Epidemiologist, HIV/STD Program, University of Washington; Public Health – Seattle & King County
- Prabhu Gounder, MD, MPH, Medical Epidemiologist, LA County Department of Public Health
- Frank Hood, Manager, Hepatitis Advocacy, The AIDS Institute
- Emalie Huriaux, STD, Adult Hepatitis, and Syringe Service Program (SSP) Manager, Washington State Department of Health
- Risha Irvin, Assistant Professor of Medicine, Division of Infectious Diseases; Associate Vice Chair for Diversity and Inclusion, Department of Medicine, Johns Hopkins University School of Medicine
- Danica Kuncio, MPH Viral Hepatitis Program Manager, Philadelphia Department of Public Health
- Kristina Larson, MPH, Hepatitis Surveillance Supervisor, Louisiana Department of Health
- Ronni Marks, Founder and Executive Director, Hepatitis C Mentor and Support Group (HCMSG)
- Lesley Miller, MD, Professor, Division of General Medicine and Geriatrics; Medical Director, Emory University; Grady Liver Clinic
- Kailynn Mitchell, MPH, Viral Hepatitis Prevention Coordinator, Wisconsin Department of Health Services
- Kate Moraras, MPH, Deputy Director of Public Health; Director, Hepatitis B Foundation; Hep B United
- Deborah Nichols, Viral Hepatitis and Harm Reduction Program Director, Indiana State Department of Health
- Monica Parker, PhD, Director, Bloodborne Viruses Laboratory, Wadsworth Center
- Adrienne Simmons, PharmD, MS, BCPS, AAHIVP, Director of Programs, National Viral Hepatitis Roundtable (NVHR)
- Lindsey Sizemore, MPH, CPH, Viral Hepatitis Program Director (Epidemiologist III), Tennessee Department of Health
- Nicola D. Thompson, PhD, Division of Viral Hepatitis, CDC
- Stacey Trooskin, MD, PhD, MPH, Chief Medical Officer; Clinical Assistant Professor of Medicine, Philadelphia FIGHT; Perelman School of Medicine, University of Pennsylvania